Clinical Trial Search

Primary: Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader. — 65; 71; 57; 59 Number of subjects

Primary: Change in HgbA1c — -1.9 percentage of glycosylated hemoglobin

Primary: Number of Participants With Successful Apheresis Collection Following Combination of AMD3100 and G-CSF. — 8; 1 participants

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants — 0.02; -0.68; -0.72; -0.82…

Primary: Recovery of the Coagulation Factors I, II, V, VII, VIII, IX, X, and XI — 8.11; 9.12; 7.08; 6.68 Percentage change

Primary: Incidence of Adverse Events. — 6 adverse events

Primary: Number of Women With Reduced Breast Parenchymal Enhancement — 7 Number of participants

Primary: Progression Free Survival (PFS) — 14.7; 15.4; 17.3 months — p=0.458

Primary: Percentage of Participants Achieving SVR12 — 51.0; 72.6 percentage of participants — p=< 0.001

Primary: Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1…

Primary: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12 — -10.40; -7.34 mm Hg — p=0.0010

Primary: Change in Pain Intensity on an 11-point Scale From Baseline to 12 Weeks — 4.0 units on a scale

Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001

Primary: Liebowitz Social Anxiety Scale (LSAS) — 68.1; 74.5; 60.0; 46.1 units on a scale

Primary: Stability of Lung Function: Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) — 98.1; 97.2 percent predicted